These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 7082547)

  • 1. The hypotensive response to hydralazine, in triple therapy, is not related to acetylator phenotype.
    Vandenburg MJ; Wright P; Holmes J; Rogers HJ; Ahmad RA
    Br J Clin Pharmacol; 1982 May; 13(5):747-50. PubMed ID: 7082547
    [No Abstract]   [Full Text] [Related]  

  • 2. Plasma concentration and acetylator phenotype determine response to oral hydralazine.
    Shepherd AM; McNay JL; Ludden TM; Lin MS; Musgrave GE
    Hypertension; 1981; 3(5):580-5. PubMed ID: 7298112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should the acetylator phenotype be determined when prescribing hydralazine for hypertension?
    Ramsay LE; Silas JH; Ollerenshaw JD; Tucker GT; Phillips FC; Freestone S
    Eur J Clin Pharmacol; 1984; 26(1):39-42. PubMed ID: 6714290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of acetylator phenotype and renal function on the antihypertensive effect of hydralazine.
    Koopmans PP; Hoefnagels WH; Huysmans FT; Thien T
    Neth J Med; 1984; 27(3):69-73. PubMed ID: 6709112
    [No Abstract]   [Full Text] [Related]  

  • 5. Determinants of response to intravenous hydralazine in hypertension.
    Shepherd A; Lin MS; McNay J; Ludden T; Musgrave G
    Clin Pharmacol Ther; 1981 Dec; 30(6):773-81. PubMed ID: 7307426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of oral hydralazine on blood pressure, cardiac output and peripheral resistance with respect to dose, age and acetylator status.
    Rowell NP; Clark K
    Radiother Oncol; 1990 Aug; 18(4):293-8. PubMed ID: 2244017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, formulation, and clinical pharmacological evaluation of hydralazine pyruvic acid hydrazone in two healthy volunteers.
    Reece PA; Stafford I; Prager RH; Walker GJ; Zacest R
    J Pharm Sci; 1985 Feb; 74(2):193-6. PubMed ID: 3989691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different phenotypes of the NAT2 gene influences hydralazine antihypertensive response in patients with resistant hypertension.
    Spinasse LB; Santos AR; Suffys PN; Muxfeldt ES; Salles GF
    Pharmacogenomics; 2014 Feb; 15(2):169-78. PubMed ID: 24444407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between the genetically determined acetylator phenotype and DNA damage induced by hydralazine and 2-aminofluorene in cultured rabbit hepatocytes.
    McQueen CA; Maslansky CJ; Glowinski IB; Crescenzi SB; Weber WW; Williams GM
    Proc Natl Acad Sci U S A; 1982 Feb; 79(4):1269-72. PubMed ID: 6951172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of intense treatment with hypotensive drugs on structural design of the resistance vessels in spontaneously hypertensive rats.
    Folkow B; Hallbäck M; Lundgren Y; Weiss L
    Acta Physiol Scand; 1971 Oct; 83(2):280-2. PubMed ID: 5114365
    [No Abstract]   [Full Text] [Related]  

  • 11. Acetylation status using hydralazine in African hypertensives at Kenyatta National Hospital.
    Rashid JR; Kofi-Tsepko ; Juma FD
    East Afr Med J; 1992 Jul; 69(7):406-8. PubMed ID: 1396201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypotensive sequelae of diazoxide and hydralazine therapy.
    Romberg GP; Lordon RE
    JAMA; 1977 Sep; 238(10):1025. PubMed ID: 577939
    [No Abstract]   [Full Text] [Related]  

  • 13. Hydralazine and beta-adrenergic blockade in the treatment of hypertension.
    Siitonen L; Jänne J; Keyriläinen O; Koskinen P; Leskinen O; Pitkäjärvi T; Reinikainen M
    Ann Clin Res; 1974 Dec; 6(6):341-6. PubMed ID: 4155933
    [No Abstract]   [Full Text] [Related]  

  • 14. Polymorphic acetylation of hydralazine.
    Timbrell JA; Harland SJ; Facchini V
    Clin Pharmacol Ther; 1980 Sep; 28(3):350-5. PubMed ID: 7408395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydralazine and prazosin in the treatment of hypertension.
    Vandenburg MJ; Sharman VL; Wright P; Drew PJ; Barnes JN
    Br J Clin Pharmacol; 1983 Nov; 16(5):537-42. PubMed ID: 6357257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihypertensive activity of cadralazine in experimental hypertensive rats.
    Takeyama K; Ikeno A; Minato H; Fukuya F; Nishimura S; Hosoki K; Kadokawa T
    Arch Int Pharmacodyn Ther; 1988; 291():163-74. PubMed ID: 3365060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Slow-release hydralazine in the treatment of essential arterial hypertension].
    Moscovici H; Yasbeck Júnior P; Fadul Neto J
    Arq Bras Cardiol; 1982 Sep; 39(3):197-9. PubMed ID: 7186366
    [No Abstract]   [Full Text] [Related]  

  • 18. Differential influence of the calcium antagonist nitrendipine and the vasodilator hydralazine on normal and elevated blood pressure.
    Knorr A; Garthoff B
    Arch Int Pharmacodyn Ther; 1984 Jun; 269(2):316-22. PubMed ID: 6476986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation of hydralazine plasma concentration to dosage and hypotensive action.
    Zacest R; Koch-Weser J
    Clin Pharmacol Ther; 1972; 13(3):420-5. PubMed ID: 5026380
    [No Abstract]   [Full Text] [Related]  

  • 20. Cardiovascular alterations in severe pregnancy-induced hypertension seen with an intravenously given hydralazine bolus.
    Cotton DB; Gonik B; Dorman KF
    Surg Gynecol Obstet; 1985 Sep; 161(3):240-4. PubMed ID: 4035539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.